Clinical Trial Update: A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated several formulations of a fixed-dose combination containing dutasteride 0.5 mg and tamsulosin 0.2 mg to identify a bioequivalent formu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Dutasteride 0.5 mg / Tamsulosin 0.2 mg fixed-dose combination (dutasteride/tamsulosin)
• Harnal-D (tamsulosin hydrochloride 0.2 mg) (tamsulosin hydrochloride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Prostatic Hyperplasia | Phase 1 | Status: COMPLETED